CN111184749B - Probiotics microbial inoculum, cotton swab, preparation method and application thereof - Google Patents
Probiotics microbial inoculum, cotton swab, preparation method and application thereof Download PDFInfo
- Publication number
- CN111184749B CN111184749B CN202010095646.8A CN202010095646A CN111184749B CN 111184749 B CN111184749 B CN 111184749B CN 202010095646 A CN202010095646 A CN 202010095646A CN 111184749 B CN111184749 B CN 111184749B
- Authority
- CN
- China
- Prior art keywords
- column body
- cotton swab
- probiotics
- probiotic
- dry ice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 125
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 125
- 229920000742 Cotton Polymers 0.000 title claims abstract description 64
- 239000002068 microbial inoculum Substances 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 230000000529 probiotic effect Effects 0.000 claims abstract description 66
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 40
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 30
- 235000011089 carbon dioxide Nutrition 0.000 claims abstract description 30
- 230000001580 bacterial effect Effects 0.000 claims abstract description 29
- 241000894006 Bacteria Species 0.000 claims abstract description 28
- 241000191963 Staphylococcus epidermidis Species 0.000 claims abstract description 18
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 12
- 239000000835 fiber Substances 0.000 claims description 15
- 239000011248 coating agent Substances 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 9
- 238000011049 filling Methods 0.000 claims description 6
- 210000000613 ear canal Anatomy 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000004804 winding Methods 0.000 claims description 3
- 241000186216 Corynebacterium Species 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 239000003814 drug Substances 0.000 abstract description 10
- 238000000859 sublimation Methods 0.000 abstract description 5
- 230000008022 sublimation Effects 0.000 abstract description 5
- 238000013461 design Methods 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 210000003454 tympanic membrane Anatomy 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 7
- 230000000813 microbial effect Effects 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 210000000959 ear middle Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 206010014025 Ear swelling Diseases 0.000 description 4
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000024036 serous otitis media Diseases 0.000 description 4
- 210000002489 tectorial membrane Anatomy 0.000 description 4
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 3
- 235000017491 Bambusa tulda Nutrition 0.000 description 3
- 241001330002 Bambuseae Species 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 239000011425 bamboo Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229960005361 cefaclor Drugs 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 244000146553 Ceiba pentandra Species 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010033078 Otitis media Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 201000010354 chronic purulent otitis media Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 210000001595 mastoid Anatomy 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 108091049293 miR-253 stem-loop Proteins 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000005923 otitis media with effusion Diseases 0.000 description 1
- 231100000199 ototoxic Toxicity 0.000 description 1
- 230000002970 ototoxic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F11/00—Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0662—Ears
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Acoustics & Sound (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a probiotic bacterial agent, a cotton swab, a preparation method and application thereof. The probiotic bacteria agent comprises staphylococcus epidermidis and bifidobacterium clavatum, and the cotton swab comprises the probiotic bacteria agent and dry ice. The preparation method of the probiotic bacterial agent and the cotton swab is simple, and the bacterial agent is prepared into a powder form, so that the viable count of the bacterial agent can be effectively maintained; the cotton swab adopts a split design, the probiotic bacteria powder and the dry ice are stored separately, the active ingredients of the probiotic bacteria agent are effectively reserved after the cotton swab is mixed in the prior art, the cotton swab is convenient to use, and the dosage of the medicine can be flexibly adjusted. The cotton swab adopts auditory canal administration, and dry ice sublimation can enable probiotics to penetrate deep into auditory canal, so that probiotics can be planted in deeper places, the effect is more direct and effective, and the effect is rapid.
Description
Technical Field
The invention relates to a probiotic bacterial agent, a cotton swab and preparation methods and applications thereof, in particular to a probiotic bacterial agent which can be prepared into a medicament for treating auditory canal diseases and preparation methods and applications thereof, and a cotton swab which can be used for treating auditory canal diseases and preparation methods and applications thereof.
Background
The normal flora exists at the position of the host communicated with the outside, a large number of normal flora exists in the external auditory canal, the normal flora is mutually restricted, the acidic environment (pH 3-5) of the skin of the auditory canal is maintained, and the physiological effects of nutrition, antagonism, immunity and the like are exerted. Analysis of the results of the auditory canal flora of the aged shows that the aged with normal hearing has fewer micro-ecological flora compared with the aged deaf, which is one of the causes of inflammation, and the scientific point of view shows that the normal flora has a certain influence on the health and the function of the auditory canal.
The inflammation of auditory canal is a common and multiple disease in children, and is isolated from auditory canal of children with otitis media patients, G + Cocci are the major pathogenic bacteria, and because of their high resistance to both penicillin and erythromycin, antibiotic treatment is a dilemma of choice. Most of clinical CSOM antibiotics (antibiotics applied to the whole body during acute attack) are applied empirically, no evidence-based medical evidence exists, particularly, blood vessel scar fibrosis under the mastoid mucosa of the middle ear can reach effective concentration only by large-scale administration, but a large amount of long-term administration not only causes drug resistance of pathogenic bacteria, but also causes destruction of beneficial bacteria and neutral bacteria, so that the CSOM treatment effect is not ideal, but large-scale or long-term use of broad-spectrum antibiotics, body immunity decline and the like causes unbalance of the flora of the auditory canal, causes inflammation and thus vicious circle. On the other hand, the administration of large doses of antibiotics may damage the eighth pair of cranial nerves, causing a number of otologic diseases including dizziness, balance imbalance, tinnitus, etc. These drugs having toxicity to otological organs are also called ototoxic drugs, and mainly include aminoglycoside antibiotics, macrolide antibiotics, amide alcohol antibiotics, and the like. In addition to hepatorenal toxicity, antibiotic drugs of abuse can trigger otic disorders, which in turn lead to hearing loss.
Disclosure of Invention
The invention aims to: the first object of the invention is to provide a probiotic bacterial agent which is easy to preserve and convenient to use; a second object is to provide a probiotic swab that acts more directly and significantly; the third purpose is to provide a preparation method of the probiotic bacterial agent and the cotton swab; a fourth object is to provide the application of the probiotic bacteria agent in preparing the medicament for treating the auditory canal diseases; a fifth object is to provide the use of said probiotic cotton swab for the treatment of otic disorders.
The technical scheme is as follows: the probiotic bacterial agent of the present invention comprises staphylococcus epidermidis and bifidobacterium clavatum.
Preferably, the viable count of the coryneform bifidobacterium is 60-80% of the total bacterial count, and the viable count of the staphylococcus epidermidis is 20-40% of the total bacterial count.
Preferably, the total bacterial count of the probiotic bacterial agent is not less than 10 7 cfu。
Wherein the viable count of staphylococcus epidermidis is 10 7 ～10 11 cfu, viable count of bifidobacterium clavatum is 10 7 ～10 11 cfu。
The probiotics are planted in human body, and the microecological balance is ensured by regulating the immune function of host mucosa and system or by regulating the flora balance. Probiotics are planted on the surface of a mucous membrane, and the probiotics are adsorbed on the surface and a membrane receptor, so that viscous proteins are degraded, and the quantity is kept stable by utilizing the endogenous nutrition, so that better metabolism and immune regulation effects can be achieved. In addition, the adherent probiotics interact with mucosal surfaces to effectively stimulate immune responses and repel pathogenic bacteria from the ear canal epithelium by competitive exclusion. The probiotics can restore the health of the auditory canal through immunoregulation, competitive inhibition, reestablishment of flora barrier and the like, and reduce the inflammation of the external auditory canal.
The staphylococcus epidermidis and the bifidobacterium clavatum are dominant strains on the surface of a human body, are safe and harmless to the human body, and can be used for a long time.
The probiotics cotton swab comprises probiotics bacteria agent, dry ice, fiber, column bodies, lining tectorial membrane and grid plates, wherein the column bodies are divided into an upper column body, a middle column body and a lower column body which are hollow structures, and the upper column body is combined with the middle column body, the middle column body and the lower column body through screw threads in a rotating way; the upper end of the upper column body is wound with fibers; the probiotic bacteria agent is contained in the middle column body, and is sealed in the middle column body by a lining coating film arranged at the upper end of the middle column body and a lining coating film arranged at the lower end of the middle column body; the lower column is filled with dry ice, and the upper end of the lower column is provided with a grid plate.
Preferably, the probiotic cotton swab contains 1-10% of the probiotic bacterial agent and 90-99% of dry ice in mass fraction.
Preferably, the aperture of the louver is no more than 1mm.
The invention adopts a method of 'fungus treatment', increases beneficial bacteria group through probiotics and inhibits antagonism harmful bacteria, and has certain curative effect on prevention and treatment of otology inflammation and recovery after healing. According to the invention, by means of a specific device, the probiotics are brought into the deep position of the auditory canal by utilizing the sublimation effect of the dry ice particles, the aerosol formed by sublimation of the dry ice is beneficial to the formation and migration of the aerosol of the probiotics, and the cooling sensation brought by the dry ice is also beneficial to the cooling of the skin, so that the comfort is brought to a patient. Dry ice volatilizes and escapes from the auditory canal, and waste accumulation in the auditory canal is not increased. Home and commercial dry ice particle makers are more common and the dry ice is easier to obtain.
The lining coating film is a paper-plastic composite film, an aluminum-plastic composite film or special paper, is air-proof and water-proof, and can be automatically broken when the pressure of the gas reaches a certain pressure, thereby being beneficial to the escape of the gas. The probiotics cotton swab is frozen and stored when flat, and if the storage environment changes due to accidental power failure or other reasons, the dry ice can break through the lining coating film and is released from the upper column body, so that the probiotics cotton swab cannot be fried.
The probiotic cotton swab adopts a split design, and the components are stored separately, so that the probiotic cotton swab can be mixed immediately before use, or can be preloaded with dry ice, and the combined package is stored in a freezing chamber. Effectively maintains the activity of the probiotics, can flexibly adjust the dosage and is convenient to use.
The preparation method of the probiotic drops comprises the following steps:
(1) Culturing probiotics;
(2) Freeze-drying probiotics;
(3) Crushing and sieving the probiotics freeze-dried powder prepared in the step (2);
(4) Mixing the probiotic bacteria powder sieved in the step (3) to prepare a probiotic bacteria agent;
(5) Filling the probiotic bacteria agent prepared in the step (4) into a cotton swab middle column body, and sealing;
(6) Winding fiber on the upper end of the upper cylinder of the cotton swab, filling dry ice and grid plates into the lower cylinder, and combining the cylinders.
Preferably, the number of the sieves in the step (3) is 80 mesh.
The particle size of the obtained probiotics powder is favorable for uniform mixing among all the bacteria powder after 80-mesh screening, and the particle size is more favorable for adhesion and field planting of probiotics and plays a role in curative effect.
The probiotic bacteria agent of the invention is applied to the preparation of medicines for treating auditory canal diseases.
The probiotic cotton swab is applied to the treatment of auditory canal diseases.
The auditory canal diseases are tinnitus, ear swelling, ear pain, external auditory canal inflammation, middle auditory canal inflammation and other diseases caused by unbalanced auditory canal flora.
The beneficial effects are that: compared with the prior art, the invention has the following remarkable advantages:
(1) The bacteria contained in the probiotic bacteria agent is safe and reliable, can be used for a long time, and the bacteria agent prepared into powder form is favorable for storage and has stable shelf life;
(2) The cotton swab adopts a split design, and the components are stored separately, so that the cotton swab can be used for mixing at present, can be preloaded for combined packaging, is flexible in mode, can effectively retain the activity of the probiotic bacteria agent, can flexibly adjust the dosage, and is convenient to use;
(3) The preparation method is simple and easy to implement, and raw materials are easy to obtain;
(4) The administration in the auditory canal can make probiotics effectively colonize the auditory canal, and has the advantages of rapid effect, more direct and effective effect, less viable bacteria count of the used strain and more remarkable treatment effect.
Drawings
FIG. 1 is a schematic diagram of the structure of the present invention;
fig. 2 is an electrootoscope view of a rat tympanic membrane, wherein fig. 2 (a) is an electrootoscope view of a normal tympanic membrane of a rat, fig. 2 (B) is an electrootoscope view of a model group rat, and fig. 2 (C) is an electrootoscope view of a tympanic membrane of a model group rat after using the probiotic cotton swab of the present invention.
Detailed Description
The technical scheme of the invention is further described below by referring to examples.
Experimental materials:
the staphylococcus epidermidis is staphylococcus epidermidis CGMCC 1.4260, the bifidobacterium clavatum is bifidobacterium clavatum CGMCC 1.2279, and the strains are purchased from China general microbiological culture collection center; the culture medium is MARS culture medium purchased from Qingdao sea blogs; absorbent cotton is purchased from national drug group, and dry ice particles are purchased from Shanghai ice-summer dry ice sales distribution company.
Experimental facilities:
MIR-253 sublimation incubator (Sanyo Co., ltd., japan), GFL002 constant temperature water bath (GFL Co., germany), GL10MA refrigerated centrifuge (Kate Co., salt city), TF-SFD refrigerated freeze dryer (Shanghai Tian Feng practice).
Example 1: probiotics cotton swab
As shown in fig. 1, the probiotic cotton swab comprises a probiotic bacterial agent, dry ice, fibers, a column body, a lining tectorial membrane and a grid plate, wherein the column body is divided into an upper column body 1, a middle column body 2 and a lower column body 3, which are hollow structures, and the column body can be made of wood, bamboo or plastic products, and the upper column body 1 is rotationally combined with the middle column body 2, the middle column body 2 and the lower column body 3 through threads; the upper end of the upper column body 1 is wound with fibers 4, the fibers 4 can be wound into a half mountain shape, a cylinder shape or a cone shape, the surface is in a concave-convex thread shape, and the fibers 4 can be cotton fibers, silk cotton mixtures, non-woven fabrics or bamboo fibers; the middle column body 2 is filled with the probiotics microbial inoculum, the probiotics microbial inoculum is sealed in the middle column body 2 by a lining coating film 5 arranged at the upper end of the middle column body 2 and a lining coating film 6 arranged at the lower end of the middle column body, and the lining coating films 5 and 6 are paper-plastic composite films, aluminum-plastic composite films or special paper; the lower column body 3 is filled with dry ice, the upper end of the lower column body 3 is provided with a grid plate 7, the aperture of the grid plate 7 is not more than 1mm, and the material is plastics, chemical fiber, cotton fiber, silk cotton mixture, non-woven fabrics or bamboo fiber.
When the cotton swab is used, the lining tectorial membrane 5 is firstly uncovered, then the upper column body 1 and the middle column body 2 are screwed and inverted, so that the probiotics microbial inoculum contacts the fiber 4, then the lining tectorial membrane 6 is uncovered, and finally the lower column body 3 and the middle column body 2 are screwed, and the cotton swab stretches into the auditory canal.
The grid plate can separate dry ice from the probiotics microbial inoculum, so that the probiotics are prevented from being subjected to moisture absorption and inactivation due to large-area frontal contact, and the aerosol formed by sublimation of the dry ice is transmitted through the grid plate to bring the probiotics into the deep position of the auditory canal for field planting, thereby playing a role.
The lining coating film can isolate air and water, and can be automatically broken when the air pressure reaches a certain pressure, thereby being beneficial to the escape of air.
Example 2: preparation of probiotics cotton swab
(1) Culturing probiotics: inoculating secondary activated probiotics into a culture medium for culturing for 20-50 hours, wherein the probiotics are staphylococcus epidermidis and bifidobacterium clavatum, and the inoculation amount is 5-10%;
(2) Lyophilization of probiotics: collecting the cultured probiotics by using a centrifugal method, freeze-drying, wherein the water content is lower than 5%, and the freeze-dried powder is reserved in a refrigerator at the temperature of minus 18 ℃;
(3) Pulverizing probiotic lyophilized powder at low temperature, and sieving with 80 mesh sieve;
(4) Mixing the probiotic bacteria powder according to the following total bacterial count proportion, namely the probiotic bacteria agent;
| probiotics | Total bacterial count ratio (%) |
| Staphylococcus epidermidis | 40 |
| Bifidobacterium clavatum | 60 |
(5) Filling the probiotic bacteria agent prepared in the step (4) into a cotton swab middle column body, and sealing;
(6) Winding the fiber on the upper end of the upper cylinder of the cotton swab, and filling dry ice and grid plates into the lower cylinder according to the following mass fractions, wherein the cylinders are combined to obtain the cotton swab.
| Component (A) | Mass fraction (%) |
| Probiotics and microbial agents | 10 |
| Dry ice | 90 |
Example 3
The difference from example 2 is that the probiotic bacterial agent and the probiotic cotton swab consist of the following respectively:
(1) Probiotics and microbial agents
| Probiotics | Total bacterial count ratio (%) |
| Staphylococcus epidermidis | 20 |
| Bifidobacterium clavatum | 80 |
(2) Probiotics cotton swab
| Component (A) | Mass fraction (%) |
| Probiotics and microbial agents | 1 |
| Dry ice | 99 |
Example 4
The difference from example 2 is that the probiotic bacterial agent and the probiotic cotton swab consist of the following respectively:
(1) Probiotics and microbial agents
| Probiotics | Total bacterial count ratio (%) |
| Staphylococcus epidermidis | 30 |
| Bifidobacterium clavatum | 70 |
(2) Probiotics cotton swab
| Component (A) | Mass fraction (%) |
| Probiotics and microbial agents | 5 |
| Dry ice | 95 |
Comparative example 1
The difference from example 2 is that the probiotic composition is as follows:
| probiotics | Total bacterial count ratio (%) |
| Staphylococcus epidermidis | 50 |
| Bifidobacterium clavatum | 50 |
Comparative example 2
The difference from example 2 is that the probiotic composition is as follows:
| probiotics | Total bacterial count ratio (%) |
| Staphylococcus epidermidis | 10 |
| Bifidobacterium clavatum | 90 |
Comparative example 3
The difference from example 2 is that the probiotic cotton swab consists of:
comparative example 4
The difference from example 2 is that the probiotic cotton swab consists of:
| component (A) | Mass fraction (%) |
| Probiotics and microbial agents | 0.5 |
| Dry ice | 99.5 |
Example 5: evaluation of the Effect of Probiotics swab on ear swelling
(1) Experimental materials
Aspirin (Jiangsu Ping pharmaceutical Co., ltd., 25 mg/tablet); xylene (AR (Shanghai); experimental instrument: electronic balance PL6001E.
Kunming mice (18-22 g) were randomly divided into 9 groups of 10 mice each, control group, aspirin group and probiotic cotton swab group.
(2) Experimental method
The number of Kunming mice was 20, and the mice were randomly divided into 10 blank groups and 10 model groups. The model group aspirates 20 μl of xylene and was uniformly spread on both the upper and lower sides of the right ear of each mouse, and the left ear was not spread as a control. After 30min of coating, 10 mice were sacrificed in the model group, two ears were cut off along the auricle baseline, and ear pieces were punched out at symmetrical positions of the left and right ears using a 6mm diameter punch. The mass of each mouse ear was weighed with a precision electronic balance, and the degree of swelling of the mouse ear (degree of swelling=mass of right ear-mass of left ear) was calculated. 10 rows of eyeballs are taken for blood taking in each group, the blood is put into an environment with the temperature of 4 ℃ and 3500r/min for centrifugation, serum is taken for detecting TNF-alpha after 15min, and whether the modeling method is successful is judged.
After the molding was judged to be effective, 90 rats were taken and administered in different groups based on the calculated amounts of the rats weight, a control group (equivalent amount of physiological saline, once daily, administration to the right ear), an aspirin group (0.2 g/kg, once daily, administration to the mouth), and a probiotic cotton swab group (probiotic 10) 8 cfu/cotton swab, probiotic cotton swabs of examples 2 to 4 and comparative examples 1 to 4 were administered once a day in the morning and evening, and the right ear was administered for 7 days, and 20. Mu.L of xylene was dropped on the right ear of the mouse after the last administration for 30min, and the left ear was used as a control, and after 15min, animals were sacrificed by pulling the neck, and after punching holes were made in the same areas along the same parts of the left and right auricles, the mixture was weighed, and the difference of the weights of the two ears was used as an index of the degree of swelling, and the results are shown in Table 1.
Table 1 evaluation of ear swelling in mice
As shown in table 1, compared with the control group, the probiotic cotton swab has obvious inhibition effect on acute inflammation ear swelling of mice, and the treatment effect is equivalent to that of aspirin; compared with the comparative example, the probiotic cotton swab has better treatment effect, so the components and the proportion of the probiotic cotton swab are the optimal scheme obtained by screening.
Example 6: evaluation of the Effect of probiotic swabs on secretory otitis media
(1) Experimental materials
Endotoxin (E.Coli: 0lll: B) Sigma, cefaclor (Shi Hualuo, 0.25 g/tablet), phosphate buffer (AR, shanghai national drug group), chloral hydrate (AR, shanghai national drug group).
Healthy SD male rats (supplied by the university of navy medical laboratory animal center) were selected to have a weight of 250-300g. The experimental animals are randomly grouped according to the weight from small to large, 10 rats are arranged in each group, and 10 groups are divided into a probiotic cotton swab group, a cefaclor group, a control group and a model group.
(2) Experimental method
An SOM rat model was established by intrathecal injection of endotoxin (E.coli: 0111: B) into the ear drum of the rat. Endotoxin was diluted to 200ng/mL in phosphate buffered saline (PBS, ph=7.4) for use. The animals were anesthetized with 10% chloral hydrate (300 mg/kg) intraperitoneally. The anterior lower quadrant of the right eardrum was aseptically injected with 50 μl of endotoxin solution (200 ng/mL), and the eardrum was observed with an electric otoscope after 48 hours.
After molding for 48 hours, the eardrum congestion, turbidity, tympanic effusion and light cone of the rat disappear by observation of an electric ear lens, and the success of molding is confirmed. The administration amount was calculated based on the body weight of the rats, and the administration amounts were controlled and controlled (equivalent physiological saline, once daily, administration to the right ear), cefaclor (0.01 g/100g, once daily, oral administration), and probiotic cotton swab (10) 8 cfu/cotton swab, probiotic cotton swabs of examples 2-4 and comparative examples 1-4, administered once a day in the morning and evening, and administered to the right ear) The administration was continued for 7 days. After 7 days, the eardrums of the rats were observed by electrootoscope, the results are shown in fig. 2; all rats were then immediately broken after blood withdrawal by cardiac puncture, dissected, fixed with 10% formaldehyde, decalcified with 5% aqueous nitric acid, sectioned with paraffin embedded after dehydration, and examined by conventional staining and light microscopy, with the results shown in table 2.
Table 2 comparison of the neutrophil counts (μm, x.+ -. S) of the mucosa of the right ear in each group
As can be seen from fig. 2, compared with the model group, the probiotic cotton swab of the present invention can reduce interstitial edema of middle ear mucosa of SOM rats and reduce inflammatory reaction of middle ear mucosa tissue.
As can be seen from table 2, compared with the model group, after the probiotic cotton swab is used for treatment, the number of neutrophils is obviously reduced, so that the interstitial edema of middle ear mucosa of the SOM rat can be relieved, the inflammatory reaction of middle ear mucosa tissue is relieved, and the treatment effect is equivalent to that of cefaclor; compared with the comparative example, the probiotic cotton swab has better treatment effect, so the components and the proportion of the probiotic cotton swab are the optimal scheme obtained by screening.
Claims (5)
1. The probiotics cotton swab is characterized by comprising probiotics bacteria agent, dry ice, fiber, a column body, a first lining coating film, a second lining coating film and a grid plate, wherein the column body is divided into an upper column body (1), a middle column body (2) and a lower column body (3) which are of hollow structures, and the upper column body (1) is combined with the middle column body (2), and the middle column body (2) is combined with the lower column body (3) through screw threads in a rotating manner; the upper end of the upper column body (1) is wound with fibers (4); the middle column body (2) is filled with the probiotics microbial inoculum, and the probiotics microbial inoculum is sealed in the middle column body (2) by a first lining coating film (5) arranged at the upper end of the middle column body (2) and a second lining coating film (6) arranged at the lower end of the middle column body; lower column(3) Dry ice is filled in the lower column body (3), and a grid plate (7) is arranged at the upper end of the lower column body; the probiotics cotton swab contains 1-10% of probiotics bacterial agent and 90-99% of dry ice; the probiotic bacterial agent consists of staphylococcus epidermidis and corynebacterium, wherein staphylococcus epidermidis is staphylococcus epidermidis CGMCC 1.4260, bifidobacterium corynebacterium is bifidobacterium corynebacterium CGMCC 1.2279, the viable count of the bifidobacterium corynebacterium is 60-80% of the total bacterial count, the viable count of staphylococcus epidermidis is 20-40% of the total bacterial count, and the total bacterial count of the probiotic bacterial agent is not lower than 10 7 cfu。
2. The probiotic cotton swab of claim 1, wherein the aperture of the grating plate is no more than 1mm.
3. A method of preparing a probiotic cotton swab of any one of claims 1 to 2, comprising the steps of:
(1) Culturing staphylococcus epidermidis and bifidobacterium clavatum of claim 1, respectively;
(2) Respectively freeze-drying the probiotics to obtain corresponding probiotics freeze-dried powder;
(3) Respectively crushing and sieving the probiotics freeze-dried powder prepared in the step (2);
(4) Mixing the probiotic bacteria powder sieved in the step (3) to prepare a probiotic bacteria agent;
(5) Filling the probiotic bacteria agent prepared in the step (4) into a cotton swab middle column body, and sealing;
(6) Winding fiber on the upper end of the upper cylinder of the cotton swab, filling dry ice and grid plates into the lower cylinder, and combining the cylinders.
4. The method of claim 3, wherein the number of the meshes of the screen in the step (3) is 80.
5. Use of a probiotic cotton swab of any one of claims 1 to 2 for the manufacture of a product for the treatment of ear canal diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010095646.8A CN111184749B (en) | 2020-02-17 | 2020-02-17 | Probiotics microbial inoculum, cotton swab, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010095646.8A CN111184749B (en) | 2020-02-17 | 2020-02-17 | Probiotics microbial inoculum, cotton swab, preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111184749A CN111184749A (en) | 2020-05-22 |
| CN111184749B true CN111184749B (en) | 2023-10-03 |
Family
ID=70687478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010095646.8A Active CN111184749B (en) | 2020-02-17 | 2020-02-17 | Probiotics microbial inoculum, cotton swab, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111184749B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101014351A (en) * | 2004-07-01 | 2007-08-08 | 布里斯托尔-迈尔斯斯奎布公司 | Method for preventing or treating respiratory infections and acute otitis media in infants |
| CN108004189A (en) * | 2018-01-18 | 2018-05-08 | 北京科拓恒通生物技术股份有限公司 | A kind of compound probiotic lactic acid bacteria powder and preparation method and application |
| WO2019180748A1 (en) * | 2018-03-21 | 2019-09-26 | Panjab University | Probiotic formulation and uses thereof |
-
2020
- 2020-02-17 CN CN202010095646.8A patent/CN111184749B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101014351A (en) * | 2004-07-01 | 2007-08-08 | 布里斯托尔-迈尔斯斯奎布公司 | Method for preventing or treating respiratory infections and acute otitis media in infants |
| CN108004189A (en) * | 2018-01-18 | 2018-05-08 | 北京科拓恒通生物技术股份有限公司 | A kind of compound probiotic lactic acid bacteria powder and preparation method and application |
| WO2019180748A1 (en) * | 2018-03-21 | 2019-09-26 | Panjab University | Probiotic formulation and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| 益生菌制剂的保健功能评价;杨隽, 潘喜华, 郑勇英, 董妙珠, 肖萍, 叶于薇, 仲伟鉴;上海预防医学杂志(02);全文 * |
| 益生菌对肠道致病菌肠粘附抑制作用;郝小燕;赵卫;曹虹;龙敏;张文炳;黄胜和;;中国公共卫生(12);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111184749A (en) | 2020-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10711292B2 (en) | Method for promoting the synthesis of collagen and proteoglycan in chondrocytes | |
| US20210177920A1 (en) | Bacteriophage treatment for acne and biofilms | |
| US11628192B2 (en) | Bacteroides fragilis for relieving endotoxin infection and application thereof | |
| CN108653263A (en) | Purposes of the chlorogenic acid and combinations thereof in the drug for preparing treatment sarcoma | |
| CN104382685A (en) | Method for preparing human vaginal microecological preparation-probiotics condom | |
| CN103249419B (en) | There is antibacterial and wound healing activity compositions | |
| CN111184749B (en) | Probiotics microbial inoculum, cotton swab, preparation method and application thereof | |
| CN113730361B (en) | Mucous membrane applicable exosome preparation with needleless injection effect and preparation method thereof | |
| CN105169464B (en) | A kind of natural honey wound dressing and preparation method and application | |
| CN113797158B (en) | Gynecological in-situ temperature-sensitive gel preparation containing active lactobacillus gasseri, and preparation and application thereof | |
| WO2015102437A1 (en) | Mugwort patch complex having moxibustion function | |
| CN105749260B (en) | Lysozyme hydrochloride vaginal tablet and preparation method and application thereof | |
| CN107848980A (en) | Suppress the composition and method of multidrug-resisting microorganism growth | |
| Binotto et al. | Poly (Lactic Acid) membrane and Sedum dendroideum extract favors the repair of burns in rats | |
| CN110917339B (en) | Lysostaphin gel and application thereof in MRSA (tissue-specific respiratory tract infection) wound surface | |
| Pongsamart et al. | Novel water soluble antibacterial dressing of durian polysaccharide gel | |
| CN211962354U (en) | Probiotics cotton swab | |
| US11419905B2 (en) | Bacteroides ovatus for relieving endotoxin infection and application thereof | |
| WO2021032179A1 (en) | Application of pseudomonas aeruginosa vaccine in treating infection associated with burn or scald injury | |
| CN117247976B (en) | Preparation of kuh-seng fermentation extract and application of kuh-seng fermentation extract in efficacy type oral care products | |
| Choi et al. | Effect of bee venom treatment in sows with oligogalactic syndrome postpartum | |
| CN104147044A (en) | Composition for treating piglet staphylococcal exudative epidermitis | |
| CN203042644U (en) | Aloe wound paste | |
| RU46935U1 (en) | MEDICINAL PREVENTIVE PRODUCT BIOSEPTIN | |
| CN111588666B (en) | Antibacterial composition, toner containing antibacterial composition and preparation method of toner |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240508 Address after: Room 801, 85 Kefeng Road, Huangpu District, Guangzhou City, Guangdong Province Patentee after: Guangzhou Dayu Chuangfu Technology Co.,Ltd. Country or region after: China Address before: 2080 Nanting Road, Fengxian District, Shanghai, 201415 Patentee before: SHANGHAI URBAN CONSTRUCTION VOCATIONAL College Country or region before: China |
|
| TR01 | Transfer of patent right |